82 FR 9383 - Agency Information Collection Activities: Proposed Collection; Comment Request; Collection of Nominations for Candidates To Serve on the Food and Drug Administration's Advisory Committees
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 23 (February 6, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 23 (February 6, 2017)
| Page Range | 9383-9385 | |
| FR Document | 2017-02412 |
[Federal Register Volume 82, Number 23 (Monday, February 6, 2017)] [Notices] [Pages 9383-9385] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-02412] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-0366] Agency Information Collection Activities: Proposed Collection; Comment Request; Collection of Nominations for Candidates To Serve on the Food and Drug Administration's Advisory Committees AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Agency's process for collecting nominations of candidates to serve on FDA's advisory committees. DATES: Submit either electronic or written comments on the collection of information by April 7, 2017. ADDRESSES: You may submit comments as follows: Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2017-N-0366 for ``Agency Information Collection Activities: Proposed Collection; Comment Request; Collection of Nominations for Candidates to Serve on FDA's Advisory Committees.'' Received comments will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food [[Page 9384]] and Drug Administration, Three White Flint North 10A63, 11601 Landsdown St., North Bethesda, MD 20852, PRAStaff@fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Process for Collecting Nominations of Candidates to Serve on FDA's Advisory Committees--OMB Control Number 0910--NEW FDA chooses to select advisory committee members through a nomination process.\1\ A person can self-nominate or be nominated by another individual. In order to identify and select qualified individuals to serve on its advisory committees, FDA has established an online portal, the FDA Advisory Committee Membership Application, to accept nominations of potential advisory committee members. --------------------------------------------------------------------------- \1\ Key point and principle I. of Appendix A to Subpart C of 41 CFR 102-3, the Federal Advisory Committee Management Final Rule notes that the Federal Advisory Committee Act does not specify the manner in which advisory committee members and staff must be appointed. --------------------------------------------------------------------------- The FDA Advisory Committee Membership Application accepts applications for Academician/Practitioner, Consumer Representative, and Industry Representative membership types. Nominees who are nominated as scientific members should be technically qualified experts in the field (e.g., clinical medicine, engineering, biological and physical sciences, biostatistics, food sciences) and have experience interpreting complex data. Candidates must be able to analyze detailed scientific data and understand its public health significance. The nomination process has recently been made electronic and is available at http://accessdata.test.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm. To submit an application, prospective nominees should upload the following documents in PDF format: \2\ (1) Curriculum vitae (CV); (2) a written confirmation that the nominee(s) is aware of the nomination (unless self-nominated); and (3) letters of recommendation are also suggested. --------------------------------------------------------------------------- \2\ 21 CFR 14.82(c). --------------------------------------------------------------------------- For Consumer Representative applications, a cover letter that lists consumer or community organizations for which the candidate can demonstrate active participation is also recommended. These documents are collected in order to determine if the nominee has the expertise in the subject matter with which the committee is concerned and has diverse professional education, training, and experience so that the committee will reflect a balanced composition of sufficient scientific expertise to handle the problems that come before it (21 CFR 14.80(b)(1)(i)). In the case of Industry and Consumer Representatives, information is collected to assess the candidate's ability to represent all interested persons within the class which the member is selected to represent (21 CFR 14.86). Each nominee should be sure to review the Agency Web site for information on: Vacancies, Qualifications, and Experience for more details concerning vacancies on each committee and the qualifications and experience common for nominees. Vacancies are updated periodically; therefore, one or more vacancies listed may be in the nomination process or a final appointment may have been made. Potential Conflicts of Interest such as financial holdings, employment, and research grants and/or contracts in order to permit evaluation of possible sources of conflict of interest. Also, FDA asks that prospective nominees inform us of how they heard about the FDA Advisory Committees (e.g., attendance at a professional meeting, an article in a publication, our Web site, while speaking with a friend or colleague). To further the Agency's goals of promoting transparency regarding the advisory committee process, FDA will also require that nominees to serve on advisory committees submit a consent form authorizing FDA to publicly post to FDA's Web site the CV submitted as part of their nomination materials, if the nominee is selected to serve on an advisory committee. In the past, FDA generally has posted the CVs of FDA advisory committee members publicly on http://www.fda.gov/AdvisoryCommittees/after reviewing the CVs and redacting information that appeared to be confidential. However, in furtherance of FDA's goal of ensuring transparency regarding the qualifications of individuals selected to serve on FDA advisory committees, and in recognition that individual advisory committee members are best situated to evaluate the confidentiality of information contained in their CVs, including any considerations raised by their relationships and agreements with third parties, FDA will now be requiring that all CVs submitted as part of the nomination process for positions on FDA advisory committees be accompanied by a written consent form stating that, if the nominee is accepted as a member of an FDA advisory committee, the individual consents to the publication of the individual's CV to FDA's Web site, without FDA removing or redacting any information. The consent form requires that the nominee affirm that the CV does not include any confidential information, including information pertaining to third parties that the nominee is not permitted to disclose. A nominee will be required to submit a signed consent form as a part of the nomination package in order for the nomination to be considered complete. All nominations for new advisory committee members will be required to be submitted through FDA's Web site at https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm, or any successor system, and the submission will be required to be accompanied by the consent form, on or after the date of OMB approval for this information collection. An estimate of the burden of this collection is provided in table 1. FDA [[Page 9385]] expects that 138.25 burden hours will be expended annually by respondents to the collection of information. FDA estimates that 553 respondents will each submit 1 application for a total of 553 annual responses. We estimate each response will require an average of 0.25 hours (15 minutes) for a total of 138.25 annual hours. Our estimate of 553 respondents is based on averaging the number of nomination submissions we have received over the past 5 fiscal years. In fiscal year (FY) 2011 we received 638 submissions; FY 2012, 603 submissions; FY 2013, 622 submissions; FY 2014, 545 submissions; and FY 2015, 357 submissions. We believe that each submission will require 15 minutes based on our experience with the submission portal. Table 1--Estimated Annual Reporting Burden \1\ -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of 21 CFR Part 14; Subpart E--Members of Number of responses per Total annual Average burden per response Total hours Advisory Committees respondents respondent responses -------------------------------------------------------------------------------------------------------------------------------------------------------- Advisory Committee Membership Applications.. 553 1 553 0.25 (15 minutes)..................... 138.25 -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Dated: February 1, 2017. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2017-02412 Filed 2-3-17; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 82, No. 23 / Monday, February 6, 2017 / Notices 9383
advisory committee member’s CV is ACTION: Notice. marked and identified, as confidential,
submitted to FDA. All information if submitted as detailed in
contained in the CV submission for SUMMARY: The Food and Drug ‘‘Instructions.’’
individuals who are selected for or Administration (FDA or Agency) is Instructions: All submissions received
currently serving on an FDA advisory announcing an opportunity for public must include the Docket No. FDA–
committee will be available for public comment on the proposed collection of 2017–N–0366 for ‘‘Agency Information
posting. Specifically, for nominees for certain information by the Agency. Collection Activities: Proposed
positions on an FDA advisory Under the Paperwork Reduction Act of Collection; Comment Request;
committee, the required consent will 1995 (PRA), Federal Agencies are Collection of Nominations for
state as follows: required to publish notice in the Candidates to Serve on FDA’s Advisory
Federal Register concerning each Committees.’’ Received comments will
If I am selected to serve on an advisory proposed collection of information and
committee, I consent to publication of my be placed in the docket and, except for
to allow 60 days for public comment in
curriculum vitae (CV), and any subsequent those submitted as ‘‘Confidential
updates to my CV that I provide FDA, on response to the notice. This notice
Submissions,’’ publicly viewable at
FDA’s Web site, without removing or solicits comments on the Agency’s
https://www.regulations.gov or at the
redacting any information. My CV does not process for collecting nominations of
Division of Dockets Management
include any confidential information, candidates to serve on FDA’s advisory
between 9 a.m. and 4 p.m., Monday
including information pertaining to third committees.
parties that I am not permitted to disclose. through Friday.
DATES: Submit either electronic or • Confidential Submissions—To
For existing advisory committee written comments on the collection of submit a comment with confidential
members who submit updated CVs, the information by April 7, 2017. information that you do not wish to be
required consent will state as follows: ADDRESSES: You may submit comments made publicly available, submit your
I consent to publication of my curriculum as follows: comments only as a written/paper
vitae (CV), and any subsequent updates to my submission. You should submit two
CV that I provide FDA, on FDA’s Web site, Electronic Submissions
copies total. One copy will include the
without removing or redacting any Submit electronic comments in the
information. My CV does not include any
information you claim to be confidential
following way: with a heading or cover note that states
confidential information, including • Federal eRulemaking Portal:
information pertaining to third parties that I ‘‘THIS DOCUMENT CONTAINS
am not permitted to disclose.
https://www.regulations.gov. Follow the CONFIDENTIAL INFORMATION.’’ The
instructions for submitting comments. Agency will review this copy, including
III. Date of Implementation Comments submitted electronically, the claimed confidential information, in
including attachments, to https:// its consideration of comments. The
All nominations for new advisory www.regulations.gov will be posted to
committee members will be required to second copy, which will have the
the docket unchanged. Because your claimed confidential information
be submitted through FDA’s Web site at comment will be made public, you are
https://www.accessdata.fda.gov/scripts/ redacted/blacked out, will be available
solely responsible for ensuring that your for public viewing and posted on
FACTRSPortal/FACTRS/index.cfm, or comment does not include any
any successor system, and the https://www.regulations.gov. Submit
confidential information that you or a both copies to the Division of Dockets
submission will be required to be third party may not wish to be posted,
accompanied by the required consent Management. If you do not wish your
such as medical information, your or name and contact information to be
form, on or after the date of OMB anyone else’s Social Security number, or
approval for this information collection. made publicly available, you can
confidential business information, such provide this information on the cover
All updated CVs for existing advisory as a manufacturing process. Please note
committee members will be required to sheet and not in the body of your
that if you include your name, contact comments and you must identify this
be submitted to FDA along with the information, or other information that
required consent form after March 8, information as ‘‘confidential.’’ Any
identifies you in the body of your information marked as ‘‘confidential’’
2017. comments, that information will be will not be disclosed except in
Dated: February 1, 2017. posted on https://www.regulations.gov. accordance with 21 CFR 10.20 and other
Leslie Kux, • If you want to submit a comment applicable disclosure law. For more
Associate Commissioner for Policy. with confidential information that you information about FDA’s posting of
[FR Doc. 2017–02411 Filed 2–3–17; 8:45 am] do not wish to be made available to the comments to public dockets, see 80 FR
BILLING CODE 4164–01–P
public, submit the comment as a 56469, September 18, 2015, or access
written/paper submission and in the the information at: http://www.fda.gov/
manner detailed (see ‘‘Written/Paper regulatoryinformation/dockets/
DEPARTMENT OF HEALTH AND Submissions’’ and ‘‘Instructions’’). default.htm.
HUMAN SERVICES Written/Paper Submissions Docket: For access to the docket to
Submit written/paper submissions as read background documents or the
Food and Drug Administration
follows: electronic and written/paper comments
[Docket No. FDA–2017–N–0366] • Mail/Hand delivery/Courier (for received, go to https://
written/paper submissions): Division of www.regulations.gov and insert the
Agency Information Collection docket number, found in brackets in the
sradovich on DSK3GMQ082PROD with NOTICES
Activities: Proposed Collection; Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers heading of this document, into the
Comment Request; Collection of ‘‘Search’’ box and follow the prompts
Nominations for Candidates To Serve Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments and/or go to the Division of Dockets
on the Food and Drug Administration’s Management, 5630 Fishers Lane, Rm.
submitted to the Division of Dockets
Advisory Committees 1061, Rockville, MD 20852.
Management, FDA will post your
AGENCY: Food and Drug Administration, comment, as well as any attachments, FOR FURTHER INFORMATION CONTACT: FDA
HHS. except for information submitted, PRA Staff, Office of Operations, Food
VerDate Sep<11>2014 16:03 Feb 03, 2017 Jkt 241001 PO 00000 Frm 00014 Fmt 4703 Sfmt 4703 E:\FR\FM\06FEN1.SGM 06FEN1](https://thefederalregister.org/doc/82_FR_9406/page/1.svg)
![Federal Register / Vol. 82, No. 23 / Monday, February 6, 2017 / Notices 9385
expects that 138.25 burden hours will hours (15 minutes) for a total of 138.25 submissions; FY 2012, 603 submissions;
be expended annually by respondents to annual hours. FY 2013, 622 submissions; FY 2014, 545
the collection of information. FDA Our estimate of 553 respondents is submissions; and FY 2015, 357
estimates that 553 respondents will each based on averaging the number of submissions. We believe that each
submit 1 application for a total of 553 nomination submissions we have submission will require 15 minutes
annual responses. We estimate each received over the past 5 fiscal years. In based on our experience with the
response will require an average of 0.25 fiscal year (FY) 2011 we received 638 submission portal.
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
21 CFR Part 14; Subpart E—Members of Advisory Number of Total annual Average burden
responses per Total hours
Committees respondents responses per response
respondent
Advisory Committee Membership Applications ............. 553 1 553 0.25 (15 minutes) 138.25
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: February 1, 2017. Time: 8:00 a.m. to 6:00 p.m. Place: National Institutes of Health, 6701
Leslie Kux, Agenda: To review and evaluate grant Rockledge Drive, Bethesda, MD 20892
applications. (Virtual Meeting).
Associate Commissioner for Policy.
Place: National Institutes of Health, 6701 Contact Person: Kristin Kramer, Ph.D.,
[FR Doc. 2017–02412 Filed 2–3–17; 8:45 am] Scientific Review Officer, Center for
Rockledge Drive, Bethesda, MD 20892
BILLING CODE 4164–01–P (Virtual Meeting). Scientific Review, National Institutes of
Contact Person: John Bishop, Ph.D., Health, 6701 Rockledge Drive, Room 5205,
Scientific Review Officer, Center for MSC 7846, Bethesda, MD 20892, (301) 437–
DEPARTMENT OF HEALTH AND Scientific Review, National Institutes of 0911, kramerkm@csr.nih.gov.
HUMAN SERVICES Health, 6701 Rockledge Drive, Room 5182, Name of Committee: Center for Scientific
MSC 7844, Bethesda, MD 20892, (301) 408– Review Special Emphasis Panel; Member
National Institutes of Health 9664, bishopj@csr.nih.gov. Conflict: Neural Trauma and Stroke.
Date: March 1, 2017.
Name of Committee: Center for Scientific Time: 1:00 p.m. to 5:30 p.m.
Center for Scientific Review; Notice of
Review Special Emphasis Panel; PAR Panel: Agenda: To review and evaluate grant
Closed Meetings Synthetic Psychoactive Drugs and Strategic applications.
Pursuant to section 10(d) of the Approaches to Counteract their Deleterious Place: National Institutes of Health, 6701
Federal Advisory Committee Act, as Effects. Rockledge Drive, Bethesda, MD 20892
amended (5 U.S.C. App.), notice is Date: February 28, 2017. (Telephone Conference Call).
Time: 2:00 p.m. to 4:30 p.m. Contact Person: Alexei Kondratyev, Ph.D.,
hereby given of the following meetings.
Agenda: To review and evaluate grant Scientific Review Officer, Center for
The meetings will be closed to the
applications. Scientific Review, National Institutes of
public in accordance with the Place: National Institutes of Health, 6701 Health, 6701 Rockledge Drive, Room 5200,
provisions set forth in sections Rockledge Drive, Bethesda, MD 20892 MSC 7846, Bethesda, MD 20892, 301–435–
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., (Virtual Meeting). 1785, kondratyevad@csr.nih.gov.
as amended. The grant applications and Contact Person: Jasenka Borzan, Ph.D., (Catalogue of Federal Domestic Assistance
the discussions could disclose Scientific Review Officer, Center for Program Nos. 93.306, Comparative Medicine;
confidential trade secrets or commercial Scientific Review, National Institutes of 93.333, Clinical Research, 93.306, 93.333,
property such as patentable material, Health, 6701 Rockledge Drive, Room 4214 93.337, 93.393–93.396, 93.837–93.844,
and personal information concerning MSC 7814, Bethesda, MD 20892–7814, 301– 93.846–93.878, 93.892, 93.893, National
individuals associated with the grant 435–1787, borzanj@csr.nih.gov. Institutes of Health, HHS)
applications, the disclosure of which Name of Committee: Center for Scientific Dated: January 30, 2017.
would constitute a clearly unwarranted Review Special Emphasis Panel; PAR16–095: Sylvia L. Neal,
invasion of personal privacy. Biopsychosocial Mechanisms in the Program Analyst, Office of Federal Advisory
Management of Chronic Conditions. Committee Policy.
Name of Committee: Center for Scientific Date: February 28–March 1, 2017.
Review Special Emphasis Panel; PAR–14– Time: 12:00 p.m. to 5:00 p.m. [FR Doc. 2017–02385 Filed 2–3–17; 8:45 am]
355 Panel: Pregnancy in Women With Agenda: To review and evaluate grant BILLING CODE 4140–01–P
Disabilities (R01). applications.
Date: February 27, 2017. Place: National Institutes of Health, 6701
Time: 12:00 p.m. to 4:00 p.m. DEPARTMENT OF HEALTH AND
Rockledge Drive, Bethesda, MD 20892
Agenda: To review and evaluate grant
applications.
(Virtual Meeting). HUMAN SERVICES
Place: National Institutes of Health, 6701 Contact Person: Unja Hayes, Ph.D.,
Rockledge Drive, Bethesda, MD 20892 Scientific Review Officer, National Institutes National Institutes of Health
(Telephone Conference Call). of Health, Center for Scientific Review, 6701
Contact Person: Martha L. Hare, RN, Ph.D., Rockledge Drive, Bethesda, MD 20892, 301– Eunice Kennedy Shriver National
Scientific Review Officer, Center for 435–1037, unja.hayes@nih.gov. Institute of Child Health & Human
Scientific Review, National Institutes of Name of Committee: Center for Scientific Development; Notice of Closed
sradovich on DSK3GMQ082PROD with NOTICES
Health, 6701 Rockledge Drive, Room 3154, Review Special Emphasis Panel; PAR16–212: Meetings
MSC 7770, Bethesda, MD 20892, (301) 451– Cognitive Neuroscience and Assessment of
8504, harem@mail.nih.gov. Cancer Treatment-Related Cognitive Pursuant to section 10(d) of the
Name of Committee: Center for Scientific Impairment. Federal Advisory Committee Act, as
Review Special Emphasis Panel; Member Date: March 1, 2017. amended (5 U.S.C. App.), notice is
Conflict: Pain and Chemosensory Time: 9:00 a.m. to 5:00 p.m. hereby given of the following meetings.
Mechanisms. Agenda: To review and evaluate grant The meetings will be closed to the
Date: February 28–March 1, 2017. applications. public in accordance with the
VerDate Sep<11>2014 16:03 Feb 03, 2017 Jkt 241001 PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 E:\FR\FM\06FEN1.SGM 06FEN1](https://thefederalregister.org/doc/82_FR_9406/page/3.svg)
Document Created: 2017-02-04 00:25:02
Document Modified: 2017-02-04 00:25:02
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Submit either electronic or written comments on the collection of information by April 7, 2017. | |
| Contact | FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North 10A63, 11601 Landsdown St., North Bethesda, MD 20852, [email protected] | |
| FR Citation | 82 FR 9383 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR